Last checked at 
(Alliance News) - Hutchmed (China) Ltd on Wednesday said it has launched a study into the combined use of Orpathys and AstraZeneca PLC's Tagrisso as a first-line treatment in certain non-small cell lung cancer patients.
The Hong-Kong based pharmaceutical company said the first patient was dosed on Tuesday in the phase III of the trial, which is named Sanovo.
"The phase III trial is a blinded, randomized, controlled study in previously untreated patients," said Hutchmed. The test aims to assess the safety and efficacy of Orpathys combined with Tagrisso in patients with locally advanced or metastatic forms of the cancers.
Orphathys, whose generic name is savolitinib, was initially developed by Hutchmed and is now being jointly progressed by Astra and Hutchmed. It is currently being trialled singularly as a treatment for gastric cancer. Tagrisso is generically known as osimertinib and was developed to treat central nervous system growths.
Shares in Hutchmed (China) Ltd were down 4.8% at 550.00 pence in London on Wednesday afternoon trade, while shares in AstraZeneca were down 1.5% at 8,344.00 pence.
By Josie O'Brien; josieobrien@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
